Biological age acceleration and the dynamic progression of cardiovascular-kidney-metabolic diseases to multimorbidity, dementia and mortality: A prospective cohort study

This prospective cohort study of over 433,000 UK Biobank participants demonstrates that biological age acceleration significantly increases the risk of transitioning from health to cardiovascular-kidney-metabolic disease, accelerates progression to multimorbidity and dementia, and reduces life expectancy, highlighting its potential as a critical biomarker for early intervention.

The Gist

Imagine your body isn't just a single machine, but a complex city with different districts: the Heart District, the Kidney District, and the Sugar Metabolism District. In this study, researchers looked at a massive city of over 430,000 people to see how the "wear and tear" on the city's infrastructure affects its future.

Here is the story of what they found, explained simply:

1. The Concept: "Biological Age" vs. "Calendar Age"

Think of your Calendar Age as the date on your driver's license. It tells you how many years you've been on Earth.
But your Biological Age is like the actual condition of your car's engine. You could be 50 years old (Calendar Age), but if you've been driving on rough roads, skipping oil changes, and using bad fuel, your engine might be worn out like a 65-year-old car. This "extra wear and tear" is called Biological Age Acceleration.

The researchers used two different "mechanic tools" (called PhenoAge and KDM-BA) to measure how fast this engine was wearing out compared to what was expected.

2. The Journey: From One Problem to a Chain Reaction

The study tracked how people moved through different stages of health, like stepping stones across a river:

• Stage 1: Healthy. (The city is running smoothly).
• Stage 2: First Problem. (One district, like the Heart, starts having issues).
• Stage 3: Multimorbidity. (Now, two or more districts are failing at the same time—e.g., Heart + Kidneys + Diabetes).
• Stage 4: Dementia & Death. (The city's central computer starts failing, and eventually, the lights go out).

3. The Big Discovery: The "Fast-Forward" Button

The study found that having a high Biological Age Acceleration is like pressing the Fast-Forward button on this journey.

• It speeds up the start: People with "older" biological ages were much more likely to get their first disease (like heart disease or diabetes) sooner than their calendar age suggested.
• It speeds up the spread: Once someone had one disease, a "fast-aging" body made it much more likely that the other districts would fail quickly, leading to a cluster of diseases (Multimorbidity).
• It speeds up the end: It also increased the risk of moving from having multiple diseases to developing dementia or passing away earlier.

The Numbers in Plain English:
If you have a high biological age acceleration, your risk of getting sick is roughly 20% to 24% higher at every single step of the journey compared to someone whose body is aging at a normal pace.

4. The "Time Travel" Effect

The researchers also calculated how much time this "fast-aging" steals from your life.

• Imagine you are walking a path. If your biological age is accelerated, it's as if the path suddenly shrinks.
• The study found that for people with multiple diseases, this acceleration shaved off about 1.36 years of life expectancy.
• For those who developed dementia, it shaved off another 0.77 years.
• Essentially, your "biological clock" is ticking faster, making the journey from health to illness happen about 1 to 2 years sooner than it should.

5. The Good News: You Can Change the Fuel

The study didn't just point out the problem; it offered a solution. They found that this "fast-forward" effect wasn't just bad luck. It was heavily influenced by your lifestyle.

Think of your lifestyle as the fuel you put in your body's engine.

• Bad Fuel: Poor diet, lack of exercise, and smoking make the engine wear out faster.
• Good Fuel: Staying active, eating well, and having a good education (which often leads to better health choices) acts like high-quality oil. It slows down the wear and tear.

The Bottom Line

This paper tells us that how old your body feels and functions is more important than how old your birthday says you are.

If you are middle-aged and worried about heart disease, diabetes, or dementia, don't just look at the calendar. Look at your "engine." By making healthy lifestyle changes now, you can slow down the biological aging process, effectively hitting the "Pause" button on the fast-forward, keeping your city's districts running smoothly for longer, and adding precious years to your life.

Technical Summary

1. Problem Statement

The study addresses a critical gap in understanding the role of biological age acceleration (BioAgeAccel) in the complex, longitudinal trajectory of health decline. Specifically, it investigates how BioAgeAccel influences the dynamic progression from a state of health to:

• The initial onset of a single Cardiovascular-Kidney-Metabolic Disease (CKMD).
• The development of CKMD Multimorbidity (CKMM) (the coexistence of two or more CKMDs).
• Subsequent transitions to dementia and mortality.

While the link between aging and individual diseases is known, the specific mechanisms and risks associated with the sequential progression from single disease to multimorbidity and neurodegenerative outcomes remain elusive.

2. Methodology

• Study Design & Population: A large-scale prospective longitudinal study utilizing data from 433,911 participants from the UK Biobank.
• Exposure Measurement: Biological aging was quantified using two distinct epigenetic clocks:
  • PhenoAge (Phenotypic Age).
  • KDM-BA (Klemera-Doubal-Bray Biological Age).
  • Acceleration was calculated as the residual difference between biological age and chronological age.
• Outcome Definitions:
  • CKMDs: Included Cardiovascular Disease (CVD), Stroke, Type 2 Diabetes (T2D), and Chronic Kidney Disease (CKD).
  • CKMM: Defined as the coexistence of $\ge$2 of the aforementioned CKMDs.
• Statistical Modeling:
  • Multistate Models: Used to estimate the hazard ratios (HRs) for transitions between specific health states (Healthy $\to$ First CKMD $\to$ CKMM $\to$ Dementia $\to$ Mortality).
  • Restricted Mean Survival Time (RMST): Employed to quantify the absolute impact of BioAgeAccel on the duration of time spent in specific states and the reduction in life expectancy.
• Covariates & Moderators: The analysis adjusted for and examined the moderating effects of age, physical activity, education, and other lifestyle factors.

3. Key Contributions

• Dynamic Progression Mapping: Unlike cross-sectional studies, this research maps the entire continuum of disease progression, linking biological aging not just to disease onset, but to the acceleration of multimorbidity and dementia.
• Quantification of Time Loss: It moves beyond relative risk (HRs) to provide absolute metrics, estimating exactly how many years of life expectancy and disease-free time are lost due to accelerated aging.
• Stratified Risk Analysis: The study identifies that the impact of BioAgeAccel is heterogeneous, being particularly potent in individuals with specific initial diagnoses (CVD or T2D) and varying by lifestyle factors.

4. Key Results

• Universal Risk Elevation: BioAgeAccel was significantly associated with increased risks across all disease transitions.
  • Healthy $\to$ First CKMD (FCKMD): HRs were 1.24 (95% CI: 1.23–1.25) for PhenoAgeAccel and 1.16 (95% CI: 1.15–1.17) for KDM-BA-Accel.
  • FCKMD $\to$ CKMM: HRs were 1.20 (PhenoAge) and 1.19 (KDM-BA).
• Dementia Transition: PhenoAgeAccel demonstrated a stronger association with the transition from CKMM to dementia (HR = 1.13) compared to transitions from healthy states or single disease states to dementia.
• Acceleration of Time:
  • BioAgeAccel shortened the time from Healthy $\to$ FCKMD by approximately 1.09 years.
  • It further shortened the time from FCKMD $\to$ CKMM by an additional 1.75 years.
• Life Expectancy Reduction:
  • Individuals with CKMM experienced an average life expectancy reduction of 1.36 years (under PhenoAge metrics).
  • Those with dementia saw a reduction of 0.77 years.
• Moderating Factors: The adverse effects of BioAgeAccel were stronger in individuals with initial CVD or T2D diagnoses and were modifiable by lifestyle factors (e.g., physical activity, education).

5. Significance and Implications

• Clinical Utility: The findings suggest that BioAgeAccel is a robust biomarker for identifying high-risk individuals who are likely to progress rapidly from single diseases to complex multimorbidity and dementia.
• Preventive Strategy: The study advocates for integrating biological age assessments into routine care for middle-aged populations.
• Intervention Target: It highlights that lifestyle interventions (physical activity, education) can mitigate the risks associated with biological aging, offering a concrete strategy to alleviate the growing burden of CKMDs and dementia.
• Policy Impact: By quantifying the "time cost" of accelerated aging, the study provides a compelling argument for early screening and intervention to extend healthspan and reduce mortality.